Format

Send to:

Choose Destination
See comment in PubMed Commons below
Leukemia. 2015 Feb;29(2):356-68. doi: 10.1038/leu.2014.207. Epub 2014 Jul 3.

The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Author information

  • 11] Department of Medical Sciences, School of Medicine and Human Genetics Foundation, University of Torino, Torino, Italy [2] Human Genetics Foundation (HuGeF), Torino, Italy.
  • 2DIMES-Section of Biochemistry AND CEBR, University of Genova, Genova, Italy.
  • 3Human Genetics Foundation (HuGeF), Torino, Italy.
  • 4Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Italy.
  • 5Division of Hematology, University of Torino, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy.
  • 6Institute of Biophysics, CNR, Genova, Italy.
  • 7Institute of Cancer & Genetics, Cardiff University, Heath Park, Cardiff, UK.

Abstract

The ecto-enzyme CD38 is gaining momentum as a novel therapeutic target for patients with hematological malignancies, with several anti-CD38 monoclonal antibodies in clinical trials with promising results. In chronic lymphocytic leukemia (CLL) CD38 is a marker of unfavorable prognosis and a central factor in the pathogenetic network underlying the disease: activation of CD38 regulates genetic pathways involved in proliferation and movement. Here we show that CD38 is enzymatically active in primary CLL cells and that its forced expression increases disease aggressiveness in a xenograft model. The effect is completely lost when using an enzyme-deficient version of CD38 with a single amino-acid mutation. Through the enzymatic conversion of NAD into ADPR (ADP-ribose) and cADPR (cyclic ADP-ribose), CD38 increases cytoplasmic Ca(2+) concentrations, positively influencing proliferation and signaling mediated via chemokine receptors or integrins. Consistently, inhibition of the enzymatic activities of CD38 using the flavonoid kuromanin blocks CLL chemotaxis, adhesion and in vivo homing. In a short-term xenograft model using primary cells, kuromanin treatment traps CLL cells in the blood, thereby increasing responses to chemotherapy. These results suggest that monoclonal antibodies that block the enzymatic activities of CD38 or enzyme inhibitors may prove therapeutically useful.

PMID:
24990614
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk